Skip to main content

HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient

Part of the Cancer Treatment and Research book series (CTAR,volume 177)

Abstract

Since their discovery as the etiologic agents of cervical cancer in the mid-1970s, human papillomaviruses (HPVs) have been linked with a growing number of epithelial-derived tumors, including head and neck squamous cell carcinomas. HPV demonstrates a particular predilection for causing tumors of the oropharynx, with the majority of cases involving infection with high-oncogenic risk HPV-16. People living with HIV are at increased risk of infection with HPV- and HPV-related oral complications even with adequate control of their HIV infection with antiretroviral therapy. In this chapter, we discuss the molecular mechanisms that underlie HPV-mediated oncogenesis in the oropharynx. We also describe the progress that has been made in understanding the epidemiology of oral HPV infection and the determinants of oral HPV-related pathology. Finally, we examine what can be done to treat and prevent oral HPV infection, benign lesions, and cancer, particularly in the context of the HIV-positive patient.

Keywords

  • Human Papillomaviruses (HPV)
  • Oropharyngeal Squamous Cell Carcinoma (OPSCC)
  • Oral Warts
  • Highly Active Antiretroviral Therapy (HAART)
  • Oral Hairy Leukoplakia

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-03502-0_6
  • Chapter length: 51 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-03502-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Fig. 6.1
Fig. 6.2
Fig. 6.3

References

  1. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136

    CAS  CrossRef  PubMed  Google Scholar 

  2. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Can Res 56:4620–4624

    CAS  Google Scholar 

  3. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K (2001) Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75:7583–7591

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  4. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR (1992) Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549–4553

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  5. Johnson DG, Schwarz JK, Cress WD, Nevins JR (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349–352

    CAS  CrossRef  PubMed  Google Scholar 

  6. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J (1983) Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 12:418–424

    CAS  CrossRef  PubMed  Google Scholar 

  7. El-Mofty SK, Lu DW (2003) Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol 27:1463–1470

    CrossRef  PubMed  Google Scholar 

  8. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL (1997) Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 123:513–516

    CAS  CrossRef  PubMed  Google Scholar 

  9. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720

    CAS  CrossRef  PubMed  Google Scholar 

  10. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR (1996) Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 2:755–762

    CAS  PubMed  Google Scholar 

  11. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG (2001) Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92:2875–2884

    CAS  CrossRef  PubMed  Google Scholar 

  12. Niedobitek G, Pitteroff S, Herbst H, Shepherd P, Finn T, Anagnostopoulos I, Stein H (1990) Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. J Clin Pathol 43:918–921

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  13. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP (1997) Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer 79:595–604

    CAS  CrossRef  PubMed  Google Scholar 

  14. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT (2002) Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8:3187–3192

    PubMed  Google Scholar 

  15. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH (2003) Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104:336–344

    CAS  CrossRef  PubMed  Google Scholar 

  16. Perry ME (1994) The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. J Anat 185(Pt 1):111–127

    PubMed Central  PubMed  Google Scholar 

  17. Brandsma JL, Abramson AL (1989) Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 115:621–625

    CAS  CrossRef  PubMed  Google Scholar 

  18. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626–1636

    CAS  CrossRef  PubMed  Google Scholar 

  19. Snijders PJ, Cromme FV, van den Brule AJ, Schrijnemakers HF, Snow GB, Meijer CJ, Walboomers JM (1992) Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 51:845–850

    CAS  CrossRef  PubMed  Google Scholar 

  20. Strome SE, Savva A, Brissett AE, Gostout BS, Lewis J, Clayton AC, McGovern R, Weaver AL, Persing D, Kasperbauer JL (2002) Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 8:1093–1100 (An official journal of the American Association for Cancer Research)

    CAS  PubMed  Google Scholar 

  21. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Can Res 63:1188–1191

    CAS  Google Scholar 

  22. Begum S, Cao D, Gillison M, Zahurak M, Westra WH (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694–5699 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  Google Scholar 

  23. Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, Eckel HE, Pfister HJ, Fuchs PG (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162:747–753

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  24. Koskinen WJ, Chen RW, Leivo I, Makitie A, Back L, Kontio R, Suuronen R, Lindqvist C, Auvinen E, Molijn A, Quint WG, Vaheri A, Aaltonen LM (2003) Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 107:401–406

    CAS  CrossRef  PubMed  Google Scholar 

  25. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH (2001) Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93:232–235

    CrossRef  PubMed  Google Scholar 

  26. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p 53 status and perturbed pRb cell cycle control. Oncogene 21:1510–1517

    CAS  CrossRef  PubMed  Google Scholar 

  27. Wilczynski SP, Lin BT, Xie Y, Paz IB (1998) Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 152:145–156

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Can Res 58:5–13

    CAS  Google Scholar 

  29. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D, Weichselbaum RR (1992) Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Can Res 52:4832–4836

    CAS  Google Scholar 

  30. Hafkamp HC, Speel EJ, Haesevoets A, Bot FJ, Dinjens WN, Ramaekers FC, Hopman AH, Manni JJ (2003) A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107:394–400

    CAS  CrossRef  PubMed  Google Scholar 

  31. Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24:841–849

    CrossRef  PubMed  Google Scholar 

  32. Snijders PJ, Steenbergen RD, Top B, Scott SD, Meijer CJ, Walboomers JM (1994) Analysis of p53 status in tonsillar carcinomas associated with human papillomavirus. J Gen Virol 75(Pt 10):2769–2775

    CAS  CrossRef  PubMed  Google Scholar 

  33. Li Y, Nichols MA, Shay JW, Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Can Res 54:6078–6082

    CAS  Google Scholar 

  34. Ohtani N, Yamakoshi K, Takahashi A, Hara E (2004) The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 51:146–153

    CrossRef  PubMed  Google Scholar 

  35. Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG (1997) Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 14:811–818

    CAS  CrossRef  PubMed  Google Scholar 

  36. Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T (2001) Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 37:498–504

    CAS  CrossRef  PubMed  Google Scholar 

  37. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469–6475 (An official journal of the American Association for Cancer Research)

    CAS  PubMed  Google Scholar 

  38. Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, Clavero O, Alos L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimera N, Lloveras B, Leon X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Felix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, Lopez-Revilla R, Mandys V, Gonzalez ME, Velasco J, Bravo IG, Quint W, Pawlita M, Munoz N, de Sanjose S, Xavier Bosch F (2016) HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403

    CrossRef  CAS  PubMed  Google Scholar 

  39. Dok R, Kalev P, Van Limbergen EJ, Asbagh LA, Vazquez I, Hauben E, Sablina A, Nuyts S (2014) p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Can Res 74:1739–1751

    CAS  CrossRef  Google Scholar 

  40. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P (2011) A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474:230–234

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  41. Sakakibara N, Mitra R, McBride AA (2011) The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol 85:8981–8995

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  42. McBride AA, Warburton A (2017) The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog 13:e1006211

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  43. Dooley KE, Warburton A, McBride AA (2016) Tandemly integrated HPV16 can form a Brd4-dependent super-enhancer-like element that drives transcription of viral oncogenes. MBio 7

    Google Scholar 

  44. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R (2014) Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci USA 111:15544–15549

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  45. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML (2014) Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24:185–199

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  46. Walline HM, Carey TE, Goudsmit CM, Bellile EL, D’Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL (2017) High-risk HPV, biomarkers, and outcome in matched cohorts of head and neck cancer patients positive and negative for HIV. Mol Cancer Res MCR 15:179–188

    CAS  CrossRef  PubMed  Google Scholar 

  47. Olthof NC, Speel EJ, Kolligs J, Haesevoets A, Henfling M, Ramaekers FC, Preuss SF, Drebber U, Wieland U, Silling S, Lam WL, Vucic EA, Kremer B, Klussmann JP, Huebbers CU (2014) Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS ONE 9:e88718

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  48. Walline HM, Goudsmit CM, McHugh JB, Tang AL, Owen JH, Teh BT, McKean E, Glover TW, Graham MP, Prince ME, Chepeha DB, Chinn SB, Ferris RL, Gollin SM, Hoffmann TK, Bier H, Brakenhoff R, Bradford CR, Carey TE, University of Michigan H, Neck Specialized Program of Research Excellence P (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840–852

    CrossRef  Google Scholar 

  49. Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, Ding W, Yu L, Wang X, Wang L, Shen H, Zhang C, Liu H, Liu X, Zhao Y, Fang X, Li S, Chen W, Tang T, Fu A, Wang Z, Chen G, Gao Q, Li S, Xi L, Wang C, Liao S, Ma X, Wu P, Li K, Wang S, Zhou J, Wang J, Xu X, Wang H, Ma D (2015) Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet 47:158–163

    CAS  CrossRef  PubMed  Google Scholar 

  50. Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582

    CrossRef  CAS  Google Scholar 

  51. Wentzensen N, Vinokurova S, von Knebel Doeberitz M (2004) Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Can Res 64:3878–3884

    CAS  CrossRef  Google Scholar 

  52. Bodelon C, Vinokurova S, Sampson JN, den Boon JA, Walker JL, Horswill MA, Korthauer K, Schiffman M, Sherman ME, Zuna RE, Mitchell J, Zhang X, Boland JF, Chaturvedi AK, Dunn ST, Newton MA, Ahlquist P, Wang SS, Wentzensen N (2016) Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis 37:188–196

    CAS  CrossRef  PubMed  Google Scholar 

  53. Safe S, Jin UH, Hedrick E, Reeder A, Lee SO (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol 28:157–172

    CrossRef  CAS  PubMed  Google Scholar 

  54. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK (2004) Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10:3825–3830 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  Google Scholar 

  55. Lleras RA, Smith RV, Adrien LR, Schlecht NF, Burk RD, Harris TM, Childs G, Prystowsky MB, Belbin TJ (2013) Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res 19:5444–5455 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  56. Sartor MA, Dolinoy DC, Jones TR, Colacino JA, Prince ME, Carey TE, Rozek LS (2011) Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6:777–787

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  57. Schlecht NF, Ben-Dayan M, Anayannis N, Lleras RA, Thomas C, Wang Y, Smith RV, Burk RD, Harris TM, Childs G, Ow TJ, Prystowsky MB, Belbin TJ (2015) Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma. Cancer Med 4:342–353

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  58. Laurson J, Khan S, Chung R, Cross K, Raj K (2010) Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31:918–926

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  59. Anayannis NV, Schlecht NF, Belbin TJ (2015) Epigenetic mechanisms of human papillomavirus-associated head and neck cancer. Arch Pathol Lab Med 139:1373–1378

    CAS  CrossRef  PubMed  Google Scholar 

  60. Kimura H, Nakamura T, Ogawa T, Tanaka S, Shiota K (2003) Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and -independent pathways. Nucleic Acids Res 31:3101–3113

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  61. Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D (2001) Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J Biol Chem 276:29116–29125

    CAS  CrossRef  PubMed  Google Scholar 

  62. Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F (2007) Viral oncoproteins target the DNA methyltransferases. Oncogene 26:1650–1655

    CAS  CrossRef  PubMed  Google Scholar 

  63. Sawada M, Kanai Y, Arai E, Ushijima S, Ojima H, Hirohashi S (2007) Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion. Cancer Lett 251:211–219

    CAS  CrossRef  PubMed  Google Scholar 

  64. van Kempen PM, Noorlag R, Braunius WW, Stegeman I, Willems SM, Grolman W (2014) Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9:194–203

    CrossRef  CAS  PubMed  Google Scholar 

  65. Wilson GA, Lechner M, Koferle A, Caren H, Butcher LM, Feber A, Fenton T, Jay A, Boshoff C, Beck S (2013) Integrated virus-host methylome analysis in head and neck squamous cell carcinoma. Epigenetics 8:953–961

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  66. Weiss D, Basel T, Sachse F, Braeuninger A, Rudack C (2011) Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation. Mol Carcinog 50:680–688

    CAS  CrossRef  PubMed  Google Scholar 

  67. van Kempen PM, van Bockel L, Braunius WW, Moelans CB, van Olst M, de Jong R, Stegeman I, van Diest PJ, Grolman W, Willems SM (2014) HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med 3:1185–1196

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  68. Chen KM, Stephen JK, Havard S, Mahan M, Divine G, Worsham MJ (2015) IGSF4 methylation as an independent marker of human papillomavirus-positive oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 141:257–263

    CrossRef  PubMed  Google Scholar 

  69. Marsit CJ, McClean MD, Furniss CS, Kelsey KT (2006) Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer 119:1761–1766

    CAS  CrossRef  PubMed  Google Scholar 

  70. Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Hofler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D, Hess J (2013) HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Investig 123:2488–2501

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  71. Miller DL, Puricelli MD, Stack MS (2012) Virology and molecular pathogenesis of HPV (human papillomavirus)-associated oropharyngeal squamous cell carcinoma. Biochem J 443:339–353

    CAS  CrossRef  PubMed  Google Scholar 

  72. Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 18:5061–5072

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  73. Veldman T, Liu X, Yuan H, Schlegel R (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci USA 100:8211–8216

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  74. Xie X, Piao L, Bullock BN, Smith A, Su T, Zhang M, Teknos TN, Arora PS, Pan Q (2014) Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene 33:1037–1046

    CAS  CrossRef  PubMed  Google Scholar 

  75. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11:726–734

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  76. Bodily JM, Mehta KP, Laimins LA (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Can Res 71:1187–1195

    CAS  CrossRef  Google Scholar 

  77. McLaughlin-Drubin ME, Crum CP, Munger K (2011) Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 108:2130–2135

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  78. Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, Peters G, Gil J (2009) Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23:1177–1182

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  79. Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Durst M, Hoppe-Seyler F (2008) Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Can Res 68:9964–9972

    CAS  CrossRef  Google Scholar 

  80. Biron VL, Mohamed A, Hendzel MJ, Alan Underhill D, Seikaly H (2012) Epigenetic differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinomas. J Otolaryngol—Head Neck Surg = Le Journal d’oto-rhino-laryngologie et de chirurgie cervico-faciale 41(1):S65–S70

    Google Scholar 

  81. Brieger J, Mann SA, Pongsapich W, Koutsimpelas D, Fruth K, Mann WJ (2012) Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med 29:505–509

    CAS  PubMed  Google Scholar 

  82. Chung YL, Lee MY, Pui NN (2009) Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30:1387–1397

    CAS  CrossRef  PubMed  Google Scholar 

  83. Diyabalanage HV, Granda ML, Hooker JM (2013) Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett 329:1–8

    CAS  CrossRef  PubMed  Google Scholar 

  84. Gasche JA, Goel A (2012) Epigenetic mechanisms in oral carcinogenesis. Future Oncol 8:1407–1425

    CAS  CrossRef  PubMed  Google Scholar 

  85. Viet CT, Dang D, Achdjian S, Ye Y, Katz SG, Schmidt BL (2014) Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. PLoS ONE 9:e112880

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  86. Lajer CB, Garnaes E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C, Nielsen FC (2012) The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 106:1526–1534

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  87. Miller DL, Davis JW, Taylor KH, Johnson J, Shi Z, Williams R, Atasoy U, Lewis JS Jr, Stack MS (2015) Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the Cancer Genome Atlas. Am J Pathol 185:679–692

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  88. Zheng ZM, Wang X (2011) Regulation of cellular miRNA expression by human papillomaviruses. Biochem Biophys Acta 1809:668–677

    CAS  PubMed  Google Scholar 

  89. Gao G, Gay HA, Chernock RD, Zhang TR, Luo J, Thorstad WL, Lewis JS Jr, Wang X (2013) A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer 119:72–80

    CAS  CrossRef  PubMed  Google Scholar 

  90. Hui AB, Lin A, Xu W, Waldron L, Perez-Ordonez B, Weinreb I, Shi W, Bruce J, Huang SH, O’Sullivan B, Waldron J, Gullane P, Irish JC, Chan K, Liu FF (2013) Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res 19:2154–2162 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  Google Scholar 

  91. Lajer CB, Nielsen FC, Friis-Hansen L, Norrild B, Borup R, Garnaes E, Rossing M, Specht L, Therkildsen MH, Nauntofte B, Dabelsteen S, von Buchwald C (2011) Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 104:830–840

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  92. Manasa VG, Kannan S (2017) Impact of microRNA dynamics on cancer hallmarks: an oral cancer scenario. Tumour Biol 39:1010428317695920

    CAS  CrossRef  PubMed  Google Scholar 

  93. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O’Sullivan B, Waldron J, Gullane P, Cummings B, Liu FF (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16:1129–1139 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  Google Scholar 

  94. Zhang X, Gee H, Rose B, Lee CS, Clark J, Elliott M, Gamble JR, Cairns MJ, Harris A, Khoury S, Tran N (2016) Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer 16:86

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  95. Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA (2011) Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 33:504–512

    CrossRef  PubMed  PubMed Central  Google Scholar 

  96. Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA (2015) MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. BMC Cancer 15:861

    CrossRef  PubMed  PubMed Central  Google Scholar 

  97. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ, Schlecht NF (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174:736–745

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  98. Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, Prystowsky MB, Schlecht NF, Segall JE, Childs G (2012) Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 180:917–928

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  99. Avissar M, McClean MD, Kelsey KT, Marsit CJ (2009) MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 30:2059–2063

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  100. Chen X, Sturgis EM, Wang C, Cao X, Li Y, Wei Q, Li G (2016) Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy. Oncotarget 7:35015–35025

    PubMed Central  PubMed  Google Scholar 

  101. Firmino N, Martinez VD, Rowbotham DA, Enfield KSS, Bennewith KL, Lam WL (2016) HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer. Oral Oncol 55:43–48

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  102. Wong N, Khwaja SS, Baker CM, Gay HA, Thorstad WL, Daly MD, Lewis JS Jr, Wang X (2016) Prognostic microRNA signatures derived from the cancer genome atlas for head and neck squamous cell carcinomas. Cancer Med 5:1619–1628

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  103. Liu S, Song L, Yao H, Zhang L, Xu D, Gao F, Li Q (2016) MiR-375 is epigenetically downregulated by HPV-16 E6 mediated DNMT1 upregulation and modulates EMT of cervical cancer cells by suppressing lncRNA MALAT1. PLoS ONE 11:e0163460

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  104. Jung HM, Phillips BL, Chan EK (2014) miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3zeta. Mol Cancer 13:80

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  105. Jeffers LK, Duan K, Ellies LG, Seaman WT, Burger-Calderon RA, Diatchenko LB, Webster-Cyriaque J (2013) Correlation of transcription of MALAT-1, a novel noncoding RNA, with deregulated expression of tumor suppressor p 53 in small DNA tumor virus models. J Cancer Ther 4(3)

    Google Scholar 

  106. Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie P, Zhou G, Li G (2014) The role of MALAT1 correlates with HPV in cervical cancer. Oncol Lett 7:2135–2141

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  107. Jimenez L, Jayakar SK, Ow TJ, Segall JE (2015) Mechanisms of invasion in head and neck cancer. Arch Pathol Lab Med 139:1334–1348

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  108. Galvan SC, Martinez-Salazar M, Galvan VM, Mendez R, Diaz-Contreras GT, Alvarado-Hermida M, Alcantara-Silva R, Garcia-Carranca A (2011) Analysis of CpG methylation sites and CGI among human papillomavirus DNA genomes. BMC Genom 12:580

    CAS  CrossRef  Google Scholar 

  109. Hatano T, Sano D, Takahashi H, Hyakusoku H, Isono Y, Shimada S, Sawakuma K, Takada K, Oikawa R, Watanabe Y, Yamamoto H, Itoh F, Myers JN, Oridate N (2017) Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. Int J Cancer 140:1571–1580

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  110. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M (2009) The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19:438–451

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  111. Mirabello L, Frimer M, Harari A, McAndrew T, Smith B, Chen Z, Wentzensen N, Wacholder S, Castle PE, Raine-Bennett T, Schiffman M, Burk RD (2015) HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int J Cancer 136:E146–E153

    CAS  CrossRef  PubMed  Google Scholar 

  112. Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS, Chae YK, Lyford-Pike S, Westra WH, Saunders JR, Sidransky D, Pai SI (2011) Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prev Res (Phila) 4:207–217

    CAS  CrossRef  Google Scholar 

  113. Zhang C, Deng Z, Pan X, Uehara T, Suzuki M, Xie M (2015) Effects of methylation status of CpG sites within the HPV16 long control region on HPV16-Positive head and neck cancer cells. PLoS ONE 10:e0141245

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  114. Reuschenbach M, Huebbers CU, Prigge ES, Bermejo JL, Kalteis MS, Preuss SF, Seuthe IM, Kolligs J, Speel EJ, Olthof N, Kremer B, Wagner S, Klussmann JP, Vinokurova S, von Knebel Doeberitz M (2015) Methylation status of HPV16 E2-binding sites classifies subtypes of HPV-associated oropharyngeal cancers. Cancer 121:1966–1976

    CAS  CrossRef  PubMed  Google Scholar 

  115. Harris RS, Dudley JP (2015) APOBECs and virus restriction. Virology 479–480:131–145

    CrossRef  CAS  PubMed  Google Scholar 

  116. Rebhandl S, Huemer M, Greil R, Geisberger R (2015) AID/APOBEC deaminases and cancer. Oncoscience 2:320–333

    CrossRef  PubMed  PubMed Central  Google Scholar 

  117. Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D (2015) APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89:688–702

    CrossRef  CAS  PubMed  Google Scholar 

  118. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, Lee D, Soares MA, Lambert PF, Howley PM, Harris RS (2014) Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 5

    Google Scholar 

  119. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833–1841

    CAS  CrossRef  PubMed  Google Scholar 

  120. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11:701–713

    CAS  CrossRef  PubMed  Google Scholar 

  121. Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM, Williams LT (1998) Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 18:5699–5711

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  122. Koncar RF, Feldman R, Bahassi EM, Hashemi Sadraei N (2017) Comparative molecular profiling of HPV-induced squamous cell carcinomas. Cancer Med 6:1673–1685

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  123. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY (2000) PIK3CA as an oncogene in cervical cancer. Oncogene 19:2739–2744

    CAS  CrossRef  PubMed  Google Scholar 

  124. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77–82

    CAS  CrossRef  PubMed  Google Scholar 

  125. Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA (2015) Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 26:1216–1223

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  126. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Trevino V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabino NB, Gomez-Macias GS, Valdez-Chapa LD, Garza-Rodriguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldana HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506:371–375

    CAS  CrossRef  PubMed  Google Scholar 

  127. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Bragelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS (2015) Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21:632–641 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  Google Scholar 

  128. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, Miller VA, Brennan TA, Henderson S, Vaz F, O’Flynn P, Kalavrezos N, Yelensky R, Beck S, Stephens PJ, Boshoff C (2013) Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 5:49

    CrossRef  PubMed  PubMed Central  Google Scholar 

  129. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3:761–769

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  130. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32:342–349

    CAS  CrossRef  PubMed  Google Scholar 

  131. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627–644

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  132. Cancer Genome Atlas Research, N., M. Albert Einstein College of, S. Analytical Biological, H. Barretos Cancer, M. Baylor College of, H. Beckman Research Institute of City of, A. Buck Institute for Research on, C. Canada’s Michael Smith Genome Sciences, S. Harvard Medical, F. G. C. C. Helen, S. Research Institute at Christiana Care Health, B. HudsonAlpha Institute for, L. L. C. Ilsbio, M. Indiana University School of, V. Institute of Human, B. Institute for Systems, C. International Genomics, B. Leidos, H. Massachusetts General, U. McDonnell Genome Institute at Washington, W. Medical College of, C. Medical University of South, C. Memorial Sloan Kettering Cancer, C. Montefiore Medical, NantOmics, I. National Cancer, A. N. National Hospital, I. National Human Genome Research, S. National Institute of Environmental Health, D. National Institute on, D. Other Communication, L. H. S. C. Ontario Tumour Bank, O. I. f. C. R. Ontario Tumour Bank, T. O. H. Ontario Tumour Bank, H. Oregon, U. Science, C.-S. M. C. Samuel Oschin Comprehensive Cancer Institute, S. R. A. International, S. St Joseph’s Candler Health, Eli, L. B. I. o. M. I. o. T. Edythe, U. Harvard, H. Research Institute at Nationwide Children’s, U. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, B. University of, M. D. A. C. C. University of Texas, H. University of Abuja Teaching, B. University of Alabama at, I. University of California, C. University of California Santa, C. University of Kansas Medical, L. University of, C. University of New Mexico Health Sciences, H. University of North Carolina at Chapel, C. University of Oklahoma Health Sciences, P. University of, R. a. P. M. S. University of Sao Paulo, C. University of Southern, W. University of, M. University of Wisconsin School of, H. Public, I. Van Andel Research, and L. Washington University in St (2017) Integrated genomic and molecular characterization of cervical cancer. Nature 543:378–384

    CrossRef  CAS  Google Scholar 

  133. Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, Wallin KL (2009) Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol 34:409–416

    CAS  PubMed  Google Scholar 

  134. Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, Odey U, Juarez-Torres E, Medina-Martinez I, Roman-Basaure E, Mitchell J, Roberson D, Sawitzke J, Garland L, Rodriguez-Herrera M, Wells D, Troyer J, Pinto FC, Bass S, Zhang X, Castillo M, Gold B, Morales H, Yeager M, Berumen J, Alvirez E, Gharzouzi E, Dean M (2015) Genome analysis of latin American cervical cancer: frequent activation of the PIK3CA pathway. Clin Cancer Res 21:5360–5370 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  135. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM (2013) PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 128:409–414

    CAS  CrossRef  PubMed  Google Scholar 

  136. Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM (2014) TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med 12:255

    CrossRef  PubMed  PubMed Central  Google Scholar 

  137. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS (2013) Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776–3783

    CAS  CrossRef  PubMed  Google Scholar 

  138. Feldman R, Gatalica Z, Knezetic J, Reddy S, Nathan CA, Javadi N, Teknos T (2016) Molecular profiling of head and neck squamous cell carcinoma. Head Neck 38(Suppl 1):E1625–E1638

    CrossRef  PubMed  Google Scholar 

  139. Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF (2010) Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) 3:1542–1551

    CAS  CrossRef  Google Scholar 

  140. Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR (2015) Increased expression of HER2, HER3, and HER2:HER3 heterodimers in HPV-positive HNSCC using a novel proximity-based assay: implications for targeted therapies. Clinical Cancer Research 21:4597–4606 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  141. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR (2017) Human Papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. Clin Cancer Res 23:3072–3083 (An official journal of the American Association for Cancer Research)

    CAS  CrossRef  PubMed  Google Scholar 

  142. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, Jr., de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE, Lux H, Investigators N (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16:583–594

    CAS  CrossRef  PubMed  Google Scholar 

  143. Lesseur C, Diergaarde B, Olshan AF, Wunsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsague X, Conway DI, Holcatova I, Mates D, Vilensky M, Healy CM, Szeszenia-Dabrowska N, Fabianova E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P (2016) Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet 48:1544–1550

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  144. Chen D, Gyllensten U (2015) Lessons and implications from association studies and post-GWAS analyses of cervical cancer. Trends Genet 31:41–54

    CAS  CrossRef  PubMed  Google Scholar 

  145. Martinez-Nava GA, Fernandez-Nino JA, Madrid-Marina V, Torres-Poveda K (2016) Cervical cancer genetic susceptibility: a systematic review and meta-analyses of recent evidence. PLoS ONE 11:e0157344

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  146. Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N (2017) TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer 123:1778–1790

    CAS  CrossRef  PubMed  Google Scholar 

  147. Cameron JE, Mercante D, O’Brien M, Gaffga AM, Leigh JE, Fidel PL Jr, Hagensee ME (2005) The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis 32:703–709

    CrossRef  PubMed  Google Scholar 

  148. Coutlee F, Trottier AM, Ghattas G, Leduc R, Toma E, Sanche G, Rodrigues I, Turmel B, Allaire G, Ghadirian P (1997) Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis 24:23–31

    CAS  CrossRef  PubMed  Google Scholar 

  149. Fakhry C, D’Souza G, Sugar E, Weber K, Goshu E, Minkoff H, Wright R, Seaberg E, Gillison M (2006) Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44:4479–4485

    CrossRef  PubMed  PubMed Central  Google Scholar 

  150. Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500–1510

    CAS  CrossRef  PubMed  Google Scholar 

  151. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420

    CrossRef  PubMed  Google Scholar 

  152. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML (2004) Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189:686–698

    CrossRef  PubMed  Google Scholar 

  153. Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, Cranston RD, Burk RD, Minkoff H, Reddy S, Xiao W, Guo Y, Gillison ML, D’Souza G (2015) Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol 181:40–53

    CrossRef  PubMed  Google Scholar 

  154. Mooij SH, van der Klis FR, van der Sande MA, Schepp RM, Speksnijder AG, Bogaards JA, de Melker HE, de Vries HJ, Snijders PJ, van der Loeff MF (2013) Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: the H2 M study. Cancer Epidemiol Biomark Prev 22:1698–1708 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)

    CrossRef  Google Scholar 

  155. Parisi SG, Cruciani M, Scaggiante R, Boldrin C, Andreis S, Dal Bello F, Pagni S, Barelli A, Sattin A, Mengoli C, Palu G (2011) Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis 11:150

    CrossRef  PubMed  PubMed Central  Google Scholar 

  156. Read TR, Hocking JS, Vodstrcil LA, Tabrizi SN, McCullough MJ, Grulich AE, Garland SM, Bradshaw CS, Chen MY, Fairley CK (2012) Oral human papillomavirus in men having sex with men: risk-factors and sampling. PLoS ONE 7:e49324

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  157. King EM, Oomeer S, Gilson R, Copas A, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P (2016) Oral human papillomavirus infection in men who have sex with men: a systematic review and meta-analysis. PLoS ONE 11:e0157976

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  158. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA (2009) Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101:1120–1130

    CrossRef  PubMed  PubMed Central  Google Scholar 

  159. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S (2005) Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425–432

    CrossRef  PubMed  Google Scholar 

  160. Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL (2008) Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol 80:953–959

    CrossRef  PubMed  Google Scholar 

  161. Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA (2016) Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS 30:1573–1582

    CAS  CrossRef  PubMed  Google Scholar 

  162. Steinau M, Reddy D, Sumbry A, Reznik D, Gunthel CJ, Del Rio C, Lennox JL, Unger ER, Nguyen ML (2012) Oral sampling and human papillomavirus genotyping in HIV-infected patients. J. Oral Pathol Med 41:288–291 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)

    CrossRef  PubMed  Google Scholar 

  163. Sirera G, Videla S, Pinol M, Canadas MP, Llatjos M, Ballesteros AL, Garcia-Cuyas F, Castella E, Guerola R, Tural C, Rey-Joly C, Clotet B (2006) High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS 20:1201–1204

    CrossRef  PubMed  Google Scholar 

  164. Fatahzadeh M, Schlecht NF, Chen Z, Bottalico D, McKinney S, Ostoloza J, Dunne A, Burk RD (2013) Oral human papillomavirus detection in older adults who have human immunodeficiency virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol 115:505–514

    CrossRef  PubMed  PubMed Central  Google Scholar 

  165. Blas MM, Brown B, Menacho L, Alva IE, Silva-Santisteban A, Carcamo C (2015) HPV prevalence in multiple anatomical sites among men who have sex with men in Peru. PLoS ONE 10:e0139524

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  166. Videla S, Darwich L, Canadas MP, Coll J, Pinol M, Garcia-Cuyas F, Molina-Lopez RA, Cobarsi P, Clotet B, Sirera G (2013) Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 40:3–10

    CrossRef  PubMed  Google Scholar 

  167. van Rijn VM, Mooij SH, Mollers M, Snijders PJ, Speksnijder AG, King AJ, de Vries HJ, van Eeden A, van der Klis FR, de Melker HE, van der Sande MA, van der Loeff MF (2014) Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLoS ONE 9:e92208

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  168. Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606–2611

    CrossRef  PubMed  Google Scholar 

  169. Richter KL, van Rensburg EJ, van Heerden WF, Boy SC (2008) Human papilloma virus types in the oral and cervical mucosa of HIV-positive South African women prior to antiretroviral therapy. J Oral Pathol Med 37:555–559 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)

    CrossRef  PubMed  Google Scholar 

  170. Ong JJ, Read TR, Vodstrcil LA, Walker S, Chen M, Bradshaw CS, Garland SM, Tabrizi SN, Cornall A, Grulich A, Hocking J, Fairley CK (2014) Detection of oral human papillomavirus in HIV-positive men who have sex with men 3 years after baseline: a follow up cross-sectional study. PLoS ONE 9:e102138

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  171. van Aar F, Mooij SH, van der Sande MA, Meijer CJ, King AJ, Verhagen DW, Heijman T, Coutinho RA, Schim van der Loeff MF (2014) Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study. BMC Infect Dis 14:668

    CrossRef  PubMed  PubMed Central  Google Scholar 

  172. D’Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL, Anastos K, Palefsky JM, Gillison ML (2007) Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121:143–150

    CrossRef  CAS  PubMed  Google Scholar 

  173. Lam JO, Bream JH, Sugar EA, Coles CL, Weber KM, Burk RD, Wiley DJ, Cranston RD, Reddy S, Margolick JB, Strickler HD, Wentz A, Jacobson L, Guo Y, Xiao W, Gillison ML, D’Souza G (2016) Association of serum cytokines with oral HPV clearance. Cytokine 83:85–91

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  174. Greenspan D, de Villiers EM, Greenspan JS, de Souza YG, zur Hausan H (1988) Unusual HPV types in oral warts in association with HIV infection. J Oral Pathol 17:482–488

    CAS  CrossRef  PubMed  Google Scholar 

  175. Anaya-Saavedra G, Flores-Moreno B, Garcia-Carranca A, Irigoyen-Camacho E, Guido-Jimenez M, Ramirez-Amador V (2013) HPV oral lesions in HIV-infected patients: the impact of long-term HAART. J Oral Pathol Med 42:443–449 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)

    CrossRef  PubMed  Google Scholar 

  176. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, Lewis CW, Salasche SJ, Turner ML, Lowery BJ (1995) Guidelines of care for warts: human papillomavirus. Committee on Guidelines of Care. J Am Acad Dermatol 32:98–103

    CAS  CrossRef  PubMed  Google Scholar 

  177. Lozada-Nur F, Glick M, Schubert M, Silverberg I (2001) Use of intralesional interferon-alpha for the treatment of recalcitrant oral warts in patients with AIDS: a report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:617–622

    CAS  CrossRef  PubMed  Google Scholar 

  178. DeRossi SS, Laudenbach J (2004) The management of oral human papillomavirus with topical cidofovir: a case report. Cutis 73:191–193

    PubMed  Google Scholar 

  179. Mun JH, Kim SH, Jung DS, Ko HC, Kim BS, Kwon KS, Kim MB (2011) Oral zinc sulfate treatment for viral warts: an open-label study. J Dermatol 38:541–545

    CAS  CrossRef  PubMed  Google Scholar 

  180. Kaur GJ, Brar BK, Kumar S, Brar SK, Singh B (2017) Evaluation of the efficacy and safety of oral isotretinoin versus topical isotretinoin in the treatment of plane warts: a randomized open trial. Int J Dermatol 56:1352–1358

    CAS  CrossRef  PubMed  Google Scholar 

  181. Snietura M, Lamch R, Kopec A, Waniczek D, Likus W, Lange D, Markowski J (2017) Oral and oropharyngeal papillomas are not associated with high-risk human papillomavirus infection. Eur Arch Otorhinolaryngol 274:3477–3483

    CrossRef  PubMed  Google Scholar 

  182. Piattelli A, Rubini C, Fioroni M, Iezzi T (2001) Warty carcinoma of the oral mucosa in an HIV+ patient. Oral Oncol 37:665–667

    CAS  CrossRef  PubMed  Google Scholar 

  183. Dona MG, Pichi B, Rollo F, Gheit T, Laquintana V, Covello R, Pescarmona E, Spriano G, Pellini R, Giuliani M, Tommasino M, Benevolo M (2017) Mucosal and cutaneous human papillomaviruses in head and neck squamous cell papillomas. Head Neck 39:254–259

    CrossRef  PubMed  Google Scholar 

  184. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612–619

    CrossRef  PubMed  Google Scholar 

  185. Gillison ML (2009) Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 21:439–444

    CrossRef  PubMed  Google Scholar 

  186. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956

    CrossRef  PubMed  Google Scholar 

  187. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187–194

    CAS  CrossRef  PubMed  Google Scholar 

  188. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67

    CrossRef  PubMed  Google Scholar 

  189. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728–736

    CrossRef  PubMed  Google Scholar 

  190. Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52:611–622

    CrossRef  PubMed  PubMed Central  Google Scholar 

  191. Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, Dubrow R, Kitahata MM, Klein MB, Burchell AN, Korthuis PT, Moore RD, D’Souza G (2014) Incidence and risk factors of HPV-related and HPV-unrelated head and neck squamous cell carcinoma in HIV-infected individuals. Oral Oncol 50:1169–1176

    CrossRef  PubMed  PubMed Central  Google Scholar 

  192. Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U (2003) Therapeutic approaches to AIDS-related malignancies. Oncogene 22:6646–6659

    CAS  CrossRef  PubMed  Google Scholar 

  193. Simard EP, Pfeiffer RM, Engels EA (2010) Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 170:1337–1345

    CrossRef  PubMed  PubMed Central  Google Scholar 

  194. Demopoulos BP, Vamvakas E, Ehrlich JE, Demopoulos R (2003) Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch Pathol Lab Med 127:589–592

    PubMed  Google Scholar 

  195. Chew EY, Hartman CM, Richardson PA, Zevallos JP, Sikora AG, Kramer JR, Chiao EY (2017) Risk factors for oropharynx cancer in a cohort of HIV-infected veterans. Oral Oncol 68:60–66

    CrossRef  PubMed  PubMed Central  Google Scholar 

  196. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, Towner WJ, Dubrow R, Quesenberry CP Jr, Neugebauer RS, Abrams DI (2011) HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomark Prev 20:2551–2559 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)

    CAS  CrossRef  Google Scholar 

  197. Picard A, Badoual C, Hourseau M, Halimi C, Pere H, Dib F, Barry B, Albert S (2016) Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma. AIDS 30:1257–1266

    CAS  CrossRef  PubMed  Google Scholar 

  198. McLemore MS, Haigentz M Jr, Smith RV, Nuovo GJ, Alos L, Cardesa A, Brandwein-Gensler M (2010) Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol 4:97–105

    CrossRef  PubMed  PubMed Central  Google Scholar 

  199. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269

    CAS  CrossRef  PubMed  Google Scholar 

  200. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A (2006) Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736–747 (Official journal of the American Society of Clinical Oncology)

    CAS  CrossRef  PubMed  Google Scholar 

  201. Kimple RJ, Harari PM (2014) Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol 50:560–564

    CrossRef  PubMed  Google Scholar 

  202. Singh B, Sabin S, Rofim O, Shaha A, Har-El G, Lucente FE (1999) Alterations in head and neck cancer occurring in HIV-infected patients–results of a pilot, longitudinal, prospective study. Acta Oncol 38:1047–1050

    CAS  CrossRef  PubMed  Google Scholar 

  203. D’Souza G, Carey TE, William WN Jr., Nguyen ML, Ko EC, Riddell JT, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL (2014) Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 65:603–610

    CrossRef  PubMed  PubMed Central  Google Scholar 

  204. Grew DJ, Cooper BT, Nguy S, Halperin J, Sanfilippo NJ (2014) Toxicity and disease-related outcomes after radiotherapy for head and neck cancer in human immunodeficiency virus-positive patients. Front Oncol 4:316

    CrossRef  PubMed  PubMed Central  Google Scholar 

  205. Mourad WF, Hu KS, Shasha D, Concert C, Ishihara D, Lin W, Gamez ME, Lukens JN, Shourbaji RA, Ryniak M, Li Z, Culliney BE, Khorsandi AS, Tran T, Jacobson A, Manolidis S, Schantz S, Urken M, Persky MS, Harrison LB (2013) Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy. Anticancer Res 33:5511–5516

    PubMed  Google Scholar 

  206. Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjonneland A, Overvad K, Quiros JR, Gonzalez CA, Sanchez MJ, Larranaga N, Navarro C, Barricarte A, Travis RC, Khaw KT, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Panico S, Masala G, Grioni S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Laurell G, Hallmans G, Manjer J, Ekstrom J, Skeie G, Lund E, Weiderpass E, Ferrari P, Byrnes G, Romieu I, Riboli E, Hildesheim A, Boeing H, Pawlita M, Brennan P (2013) Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31:2708–2715 (Official journal of the American Society of Clinical Oncology)

    CrossRef  PubMed  PubMed Central  Google Scholar 

  207. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS (2001) Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357:1411–1412

    CAS  CrossRef  PubMed  Google Scholar 

  208. Ortega KL, Vale DA, Magalhaes MH (2009) Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients. J Oral Pathol Med 38:489–494 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)

    CAS  CrossRef  PubMed  Google Scholar 

  209. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000) Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89:299–304

    CAS  CrossRef  Google Scholar 

  210. Tappuni AR, Fleming GJ (2001) The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:623–628

    CAS  CrossRef  PubMed  Google Scholar 

  211. Leigh J (2000) Oral warts rise dramatically with use of new agents in HIV. HIV Clin 12:7

    Google Scholar 

  212. King MD, Reznik DA, O’Daniels CM, Larsen NM, Osterholt D, Blumberg HM (2002) Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 34:641–648

    CrossRef  PubMed  Google Scholar 

  213. Batavia AS, Secours R, Espinosa P, Jean Juste MA, Severe P, Pape JW, Fitzgerald DW (2016) Diagnosis of HIV-associated oral lesions in relation to early versus delayed antiretroviral therapy: results from the CIPRA HT001 trial. PLoS ONE 11:e0150656

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  214. Lilly EA, Cameron JE, Shetty KV, Leigh JE, Hager S, McNulty KM, Cheeks C, Hagensee ME, Fidel PL Jr (2005) Lack of evidence for local immune activity in oral hairy leukoplakia and oral wart lesions. Oral Microbiol Immunol 20:154–162

    CAS  CrossRef  PubMed  Google Scholar 

  215. Danaher RJ, Wang C, Roland AT, Kaetzel CS, Greenberg RN, Miller CS (2010) HIV protease inhibitors block oral epithelial cell DNA synthesis. Arch Oral Biol 55:95–100

    CAS  CrossRef  PubMed  Google Scholar 

  216. Badley AD (2005) In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 12(Suppl 1):924–931

    CAS  CrossRef  PubMed  Google Scholar 

  217. Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? The Lancet. Oncology 10:61–71

    CAS  PubMed  Google Scholar 

  218. Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA (2013) HPV-related cancers after solid organ transplantation in the United States. Am J Transplant 13:3202–3209 (Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  219. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H, Bower M (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27:884–890

    CrossRef  PubMed  Google Scholar 

  220. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellu F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S (2009) Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 100:840–847

    CrossRef  Google Scholar 

  221. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651

    CAS  CrossRef  PubMed  Google Scholar 

  222. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032

    CrossRef  PubMed  Google Scholar 

  223. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother. 10:2147–2162

    CrossRef  Google Scholar 

  224. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 14:467–475 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)

    CAS  CrossRef  Google Scholar 

  225. Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, Lynch CF, Wilkinson EJ, Hernandez BY, Copeland G, Saber MS, Hopenhayn C, Huang Y, Cozen W, Lyu C, Unger ER (2014) Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 20:822–828

    CrossRef  PubMed  PubMed Central  Google Scholar 

  226. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M (2016) Human Papillomavirus-associated cancers - United States, 2008–2012. MMWR Morb Mortal Wkly Rep 65:661–666

    CrossRef  PubMed  Google Scholar 

  227. Cameron JE, Snowhite IV, Chaturvedi AK, Hagensee ME (2003) Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol 10:431–438

    CAS  PubMed Central  PubMed  Google Scholar 

  228. Marais DJ, Best JM, Rose RC, Keating P, Soeters R, Denny L, Dehaeck CM, Nevin J, Kay P, Passmore JA, Williamson AL (2001) Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J Med Virol 65:149–154

    CAS  CrossRef  PubMed  Google Scholar 

  229. Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, Pan Y, Lazcano-Ponce E, Salmeron J, Giuliano AR (2016) Quadrivalent Human Papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial. J Infect Dis 214:1276–1283

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  230. Rowhani-Rahbar A, Carter JJ, Hawes SE, Hughes JP, Weiss NS, Galloway DA, Koutsky LA (2009) Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 200:1452–1455

    CAS  CrossRef  PubMed  Google Scholar 

  231. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8:e68329

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  232. Hirth JM, Chang M, Resto VA (2017) Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old). Vaccine 35:3446–3451

    CrossRef  PubMed  Google Scholar 

  233. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A (2010) Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 55:197–204

    CrossRef  PubMed  PubMed Central  Google Scholar 

  234. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM (2010) Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202:1246–1253

    CrossRef  PubMed  Google Scholar 

  235. Meites E, Kempe A, Markowitz LE (2016) Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 65:1405–1408

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Hagensee .

Editor information

Editors and Affiliations

Appendix

Appendix

Table 6.1 List of abbreviations used in this chapter

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Cameron, J.E., Hagensee, M. (2019). HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. In: Meyers, C. (eds) HIV/AIDS-Associated Viral Oncogenesis. Cancer Treatment and Research, vol 177. Springer, Cham. https://doi.org/10.1007/978-3-030-03502-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03502-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03501-3

  • Online ISBN: 978-3-030-03502-0

  • eBook Packages: MedicineMedicine (R0)